EU Pharmacovigilance
Explore all topics, guides, and frameworks related to EU Pharmacovigilance.
Articles in this section
82- GVP Module VI: Seriousness, Expectedness and ICSR Case Assessment Explains how seriousness and expectedness differ from validity and causality, how cases should be assessed consistently, and where common classification errors create regulatory and data-quality risks. Read Article →
- GVP Module VIII: Imposed and Non-Imposed PASS A structured explanation of imposed and non-imposed PASS, including legal status, RMP studies, voluntary studies, regulatory procedures, responsibilities and practical decision-making. Read Article →
- EU Pharmacovigilance Inspection Findings: Cross-Functional and Interface Controls A practical framework for understanding how inspectors test whether pharmacovigilance responsibilities and information flows remain effective across organisational boundaries. Read Article →
- GVP Module XVI: Pregnancy Prevention Programmes in the EU — Risk Minimisation and Member State Implementation A practical guide to pregnancy prevention programmes for medicinal products with embryo-fetal risks, covering the EU regulatory framework, selection of measures, patient and healthcare-professional controls, implementation, effectiveness and differences in Member State practice. Read Article →
- Controlled Access and Controlled Distribution of Medicines in the EU: Non-Pregnancy Risk-Minimisation Approaches and Member State Implementation A practical GVP Module XVI guide to controlled access and controlled distribution outside pregnancy prevention programmes, including specialist prescribing, testing, authorised providers, treatment centres, traceability, examples and the EU-to-national implementation interface. Read Article →
- GVP Module XVI: Difficult Risk Minimisation Measures and Adaptation A practical framework for recognising ineffective or unintended risk minimisation, distinguishing implementation failure from design failure, and using evidence to adapt measures throughout the product lifecycle. Read Article →
- GVP Module XVI: Defining Risk Minimisation Objectives and Implementation Pathways A practical framework for moving from a characterised safety concern to a measurable risk minimisation objective, proportionate intervention and controlled implementation. Read Article →
- GVP Module XVI: Selecting Risk Minimisation Measures in Practice A practical guide to choosing routine and additional risk minimisation measures by linking the safety problem, target behaviour, healthcare context, implementation pathway and effectiveness objective. Read Article →
- GVP Module XVI: Risk Minimisation Effectiveness Evaluation A practical framework for designing, measuring and interpreting risk-minimisation effectiveness, including implementation, behavioural change, clinical outcomes, study design and decision-making. Read Article →
- GVP Module XVI: Educational Materials as Additional Risk Minimisation Measures A practical framework for linking educational materials to a defined safety concern, risk-minimisation objective, target audience, required behaviour, implementation process and effectiveness evaluation. Read Article →
- GVP Module XVI: Routine and Additional Risk Minimisation Measures A detailed guide to the distinction between routine and additional risk minimisation, including selection principles, implementation pathways, examples and the relationship with the risk management plan. Read Article →
- Pharmacovigilance in Older People: Geriatric Considerations A practical framework for recognising, assessing and managing safety information in older patients while distinguishing age-related vulnerability from medicine-related risk. Read Article →
- GVP Product- or Population-Specific Considerations IV: Paediatric Population A practical framework for interpreting paediatric safety evidence across age groups, developmental stages, exposure, clinical context, adverse reactions and lifecycle surveillance. Read Article →
- GVP Product- or Population-Specific Considerations III: Pregnancy and Breastfeeding A practical framework for collecting, evaluating and communicating safety information in pregnancy and breastfeeding while balancing maternal, fetal, neonatal and infant risks and benefits. Read Article →
- GVP Product- or Population-Specific Considerations III: Pregnancy and Breastfeeding A practical framework for evaluating maternal, fetal, neonatal and infant safety, collecting pregnancy and breastfeeding exposure data, and interpreting risks without unnecessarily withholding useful treatment. Read Article →
- GVP Product- or Population-Specific Considerations II: Biological Medicinal Products A practical explanation of why biological medicines require product-specific pharmacovigilance attention, including identification, immunogenicity, traceability, interchangeability, biosimilars and signal assessment. Read Article →
- GVP Product- or Population-Specific Considerations I: Vaccines A practical explanation of how the EU pharmacovigilance framework applies specifically to prophylactic vaccines and why vaccine safety surveillance requires additional clinical, epidemiological and programme-level considerations. Read Article →
- GVP Module XVI: Risk Minimisation Measures A practical framework for understanding routine and additional risk minimisation, their relationship with the risk management plan, stakeholder needs, implementation and effectiveness evaluation. Read Article →
- GVP Module XV: Safety Communication A practical framework for communicating emerging and established safety information accurately, proportionately and consistently across patients, healthcare professionals, regulators and other audiences. Read Article →
- GVP Module X: Additional Monitoring of Medicinal Products A practical explanation of what additional monitoring means, why a medicine receives the status, how the EU symbol and statement are used, and what additional monitoring does and does not imply. Read Article →
- GVP Module IX: Special Situations and Difficult Signals A practical framework for managing signals that do not fit a simple detection-to-confirmation pathway, with emphasis on uncertainty, competing explanations, urgency and proportionate governance. Read Article →
- GVP Module IX: Signal Management in EudraVigilance and the EU Regulatory Network A practical explanation of the EU regulatory-network signal-management process, including EudraVigilance monitoring, work sharing, signal confirmation, PRAC assessment, tracking and regulatory follow-up. Read Article →
- GVP Module IX: Signal Management Quality and Effectiveness A practical framework for designing, monitoring and improving signal management so that detection, assessment, decisions and follow-up remain timely, traceable and scientifically effective. Read Article →
- GVP Module IX: Signal Management Documentation, Records and Inspection Evidence A practical framework for preserving the evidence, reasoning, decisions and actions that demonstrate effective signal management and support inspection readiness. Read Article →
- GVP Module IX: MAH and QPPV Responsibilities in Signal Management A practical framework for understanding ownership, assessment, escalation, regulatory communication, documentation and QPPV oversight throughout the signal-management lifecycle. Read Article →
- GVP Module IX: Signal Outcomes and Regulatory Action A systematic guide to the outcomes of signal assessment, from continued monitoring and further evidence generation to changes in product information, risk management and regulatory action. Read Article →
- GVP Module IX: Evidence, Causality and Clinical Context A systematic guide to weighing case-level, epidemiological, clinical and mechanistic evidence when assessing a potential safety signal and determining what the evidence supports. Read Article →
- GVP Module IX: Signal Analysis and Prioritisation A systematic guide to turning a validated signal into a proportionate assessment plan, balancing evidence strength, clinical seriousness, public-health impact, uncertainty and urgency. Read Article →
- GVP Module IX: Signal Detection, Validation and Confirmation A systematic guide to the transition from a safety observation to a validated signal and, where justified, a confirmed safety concern, with emphasis on evidence, clinical context and documented decision-making. Read Article →
- GVP Module IX: Signal Management Explained A systematic guide to how pharmacovigilance signals are identified, evaluated and managed, and how signal management connects evidence, clinical judgement, governance and regulatory decision-making. Read Article →
- GVP Module VIII: PASS Inspection and Audit Findings A practical inspection-focused guide to PASS evidence, traceability, study governance, data quality, regulatory commitments and the distinction between illustrative failure modes and documented inspection findings. Read Article →
- GVP Module VIII: PASS in the Risk Management Plan A structured explanation of PASS within the RMP, from the safety question and pharmacovigilance plan through study design, regulatory commitments, results and lifecycle updates. Read Article →
- GVP Module VIII Addendum I: Submission of Information on Non-Interventional PASS A practical guide to the submission architecture for non-interventional PASS, distinguishing legal submission obligations, recommendations, national procedures, EU procedures and study registration. Read Article →
- GVP Module VIII: Imposed and Non-Imposed PASS A structured explanation of imposed and non-imposed PASS, showing how the regulatory basis determines the applicable procedure, responsibilities, documentation and oversight. Read Article →
- GVP Module VIII: PASS Results, Reporting and Regulatory Follow-up A structured explanation of how PASS results are interpreted, reported and connected to the wider safety-management and regulatory system, with clear distinctions between final, interim and regulatory outcomes. Read Article →
- GVP Module VIII: PASS Governance, Oversight and Quality Management A practical framework for governing PASS activities, including roles, oversight, quality planning, vendor management, study conduct and escalation. Read Article →
- GVP Module VIII: PASS Protocols, Objectives and Study Design A practical guide to PASS protocol development, covering the research question, objectives, study design, population, variables, data sources, analysis, bias and regulatory expectations. Read Article →
- GVP Module VIII: Non-Interventional PASS Requirements A practical guide to non-interventional PASS requirements, including usual care, treatment decisions, study inclusion, additional procedures, epidemiological methods and regulatory classification. Read Article →
- GVP Module VIII: Post-Authorisation Safety Studies Explained A practical foundation for understanding PASS under GVP Module VIII, including what qualifies as a PASS, why studies are conducted, who is responsible and how imposed and voluntary studies fit into EU pharmacovigilance. Read Article →
- GVP Module VIII: When Is a PASS Needed? A practical framework for deciding when additional post-authorisation safety evidence is needed, distinguishing regulatory obligations from risk-management needs and voluntary evidence generation. Read Article →
- GVP Module VII: PSUR Inspection Findings and Common Deficiencies A practical inspection-focused guide to PSUR deficiencies, including scientific quality, data integrity, governance, submission controls, benefit-risk assessment and evidence of effective implementation. Read Article →
- GVP Module VII: PSUR Quality Control and Inspection Readiness A practical framework for controlling PSUR quality, completeness, traceability and regulatory follow-up, with emphasis on inspection readiness and QPPV oversight. Read Article →
- GVP Module VII: PSUR Assessment, PRAC and Regulatory Follow-Up A practical explanation of the EU PSUR assessment process, PRAC involvement, regulatory outcomes, MAH responses and follow-up activities after a periodic safety assessment. Read Article →
- GVP Module VII: PSUR Single Assessment and EU Procedures A practical explanation of PSUR single assessment, the EU regulatory procedure, the roles of MAHs and authorities, and how periodic safety evaluation can lead to coordinated regulatory action. Read Article →
- GVP Module VII: Multiple Products, Substances and Marketing Authorisation Holders A practical explanation of how PSUR scope is coordinated across products and marketing authorisation holders, including single PSUR principles, active-substance scope, product differences and EU single assessment. Read Article →
- GVP Module VII: Actions Taken and Regulatory Implications A practical explanation of safety-related actions in the PSUR, including actions during the reporting interval, proposed changes, regulatory consequences, implementation and follow-up. Read Article →
- GVP Module VII: Benefit-Risk Evaluation in the PSUR A practical, evidence-based explanation of how PSUR benefit-risk evaluation integrates key benefits and risks, medical need, alternatives, uncertainty and the totality of evidence into a defensible regulatory conclusion. Read Article →
- GVP Module VII: Writing the PSUR Safety Evaluation A practical, evidence-based guide to writing a PSUR safety evaluation, including critical analysis, characterisation of risks and benefits, uncertainty, cumulative evidence and defensible conclusions. Read Article →
- GVP Module VII: PSUR Reference Data and International Safety Information A practical explanation of reference information, reference safety information, international safety data and the controls needed to interpret changes consistently in an EU PSUR. Read Article →
- GVP Module VII: PSUR Data Lock Point and Reporting Interval A practical explanation of the PSUR reporting period, data lock point, EU reference dates and the controls needed to ensure that the correct safety information is included in each periodic assessment. Read Article →
- GVP Module VII: PSUR Scope, Objectives and Regulatory Purpose A practical explanation of why the EU PSUR exists, what it is intended to evaluate, what falls within its scope, and how periodic safety evaluation supports regulatory oversight and benefit-risk assessment. Read Article →
- What Are EU Good Pharmacovigilance Practices (GVP)? Introduces EU Good Pharmacovigilance Practices, explaining their legal context, structure, role in the pharmacovigilance system, relationship with legislation and practical importance for MAHs, QPPVs and inspections. Read Article →
- How to Read and Apply EU GVP Guidance in Practice Provides a practical method for interpreting EU GVP guidance, distinguishing legal requirements from guidance, translating expectations into operational controls and demonstrating effective implementation during audits and inspections. Read Article →
- GVP Module VI: Case Intake, Triage and Initial Assessment Explains how potential safety information is received, recognised, logged, dated, triaged and initially assessed under GVP Module VI before validation and case processing. Read Article →
- GVP Module I Explained: Pharmacovigilance Systems and Quality Systems Explains the EU GVP Module I framework for pharmacovigilance systems and quality systems, including governance, responsibilities, controls, evidence, QPPV oversight and inspection readiness. Read Article →
- GVP Module VII Explained: The EU PSUR A textbook-style introduction to the EU PSUR: what it is, why it exists, how it fits into pharmacovigilance, and how MAHs should govern its preparation and submission. Read Article →
- GVP Module VI: Sources of Individual Case Safety Reports A practical, source-based explanation of spontaneous, solicited and other ICSR sources, including source classification, primary-source identification and operational controls. Read Article →
- GVP Module VI Inspection Findings: Common ICSR Case-Processing Deficiencies A practical inspection-focused guide to recurring weaknesses in individual case safety report processing and the evidence that demonstrates effective control. Read Article →
- GVP Module VI: Follow-Up of Individual Case Safety Reports Explains why follow-up is performed, how cases should be identified and prioritised, and how targeted follow-up can improve the scientific value of an ICSR without creating unnecessary burden. Read Article →
- GVP Module VI: Data Quality, Case Processing Controls and Reconciliation Explains how MAHs can control ICSR data quality from intake through submission, follow-up and reconciliation, with an inspection-ready focus. Read Article →
- GVP Module VI: Electronic Submission and EudraVigilance Interfaces Explains how valid post-authorisation ICSRs move into EudraVigilance, the distinction between EVPM and EVCTM, gateway and EVWEB pathways, acknowledgements, data standards, rerouting and inspection-ready submission controls. Read Article →
- GVP Module VI: Other Organised Data Collection Systems and Solicited Sources Explains how market research, registries, non-interventional studies, disease-management programmes and other organised data-collection systems are classified, assessed and connected to ICSR processing. Read Article →
- GVP Module VI: Medical Literature Monitoring and Literature ICSRs Explains how medical literature becomes a source of ICSRs under GVP Module VI, how EMA's Medical Literature Monitoring service operates, how search strategies are constructed and maintained, how literature records are screened and assessed, and how literature cases are classified when they arise from spontaneous observations or studies. Read Article →
- GVP Module VI: Clinical Trials and ICSR Management Explains how clinical-trial safety reporting interfaces with the EU pharmacovigilance system, why the applicable regulatory framework matters, and how sponsors and MAHs should distinguish trial safety reporting from post-authorisation ICSR processing. Read Article →
- GVP Module VI: Patient Support Programmes and Solicited Reports Explains how patient support programmes are classified, when safety information is solicited, how valid ICSRs are assessed and reported, and what MAHs should control across PSP operations, vendors and pharmacovigilance processes. Read Article →
- GVP Module VI: Difficult ICSR Validity and Assessment Scenarios Explains how to distinguish safety-relevant information from a valid ICSR, apply the minimum validity criteria to difficult scenarios, avoid unsupported assumptions and document defensible case-processing decisions. Read Article →
- GVP Module VI: Causality Assessment and Clinical Evaluation of ICSRs Explains how causality should be considered in ICSR assessment, the evidence that informs clinical evaluation, the limits of causality categories, and the distinction between causality, seriousness and expectedness. Read Article →
- GVP Module VI: Special Situations in ICSR Management Explains how special situations should be identified, assessed and documented within the ICSR process, with particular attention to distinguishing exposure from adverse reactions and determining when reporting or follow-up is required. Read Article →
- GVP Module VI: ICSR Follow-Up and Medical Review Explains how follow-up should be planned, performed, documented and medically assessed throughout the ICSR lifecycle, including when new information changes the case. Read Article →
- GVP Module VI: ICSR Validity, Minimum Information and Case Assessment Explains how pharmacovigilance teams assess the minimum information required for a valid ICSR, distinguish incomplete cases from invalid reports, manage uncertainty and maintain traceability from initial information through case processing. Read Article →
- GVP Module VI: Duplicate ICSR Identification and Management Explains how duplicate ICSRs arise, how to identify and confirm potential duplicates, how to link and merge cases appropriately, and how duplicate management affects reporting, signal detection and inspection readiness. Read Article →
- EudraVigilance Data for MAHs: ICSR Monitoring and Safety Use Explains what MAHs need to monitor and retrieve from EudraVigilance, what the information is used for, and how mandatory regulatory activities differ from recommended or scientifically useful uses. Read Article →
- GVP Module VI: ICSR Data Quality, Follow-Up and Reconciliation Explains how pharmacovigilance organisations can maintain accurate, complete and traceable ICSRs from initial receipt through follow-up, regulatory submission and final reconciliation. Read Article →
- GVP Module VI: Literature Cases and ICSR Management Explains the pharmacovigilance literature-monitoring pathway from article identification and screening through case extraction, duplicate assessment, reporting, follow-up and inspection oversight. Read Article →
- GVP Module VI: Special Situations and ICSR Reporting Explains how important special situations should be assessed and managed within the EU ICSR process, including when they generate reportable adverse reaction information and how to control the interfaces between pharmacovigilance functions. Read Article →
- GVP Module VI Addendum II: Masking Personal Data in Individual Case Safety Reports Explains the practical principles for protecting personal data in ICSRs while preserving the information needed for safe and effective pharmacovigilance. Read Article →
- GVP Module VI: Electronic ICSR Submission and EudraVigilance Explains the operational controls required to move an ICSR from a completed safety case to a valid electronic regulatory submission through the EU EudraVigilance environment. Read Article →
- GVP Module VI: Collection, Management and Submission of Reports of Suspected Adverse Reactions to Medicinal Products A detailed practical guide to GVP Module VI and the end-to-end management of suspected adverse reaction reports in the EU pharmacovigilance system. Read Article →
- GVP Module VI: Duplicate Management of Suspected Adverse Reaction Reports Explains how to identify and manage duplicate individual case safety reports while preserving complete safety information and reliable pharmacovigilance analyses. Read Article →
- GVP Module V: Risk Management Systems Explains how GVP Module V turns pharmacovigilance risk management into a lifecycle system for identifying, evaluating and controlling important risks of medicines. Read Article →
- GVP Module IV: Pharmacovigilance Audits Explains how GVP Module IV translates the EU pharmacovigilance audit framework into a risk-based, independent and inspection-ready audit programme. Read Article →
- GVP Module II Explained: The Pharmacovigilance System Master File The Pharmacovigilance System Master File (PSMF) is the central description of how an EU marketing authorisation holder's pharmacovigilance system is organised and controlled. This article explains what GVP Module II requires and how the PSMF should work in practice. Read Article →